Lorazepam

The global prevalence of anxiety disorders has exceeded 3.8%, and sedative-hypnotic drugs are one of the core clinical solutions for such diseases. Lorazepam is a benzodiazepine central nervous system inhibitor. By enhancing the binding efficiency of γ-aminobutyric acid to GABAA receptors, it inhibits abnormal discharge of neurons, and exerts the effects of anti-anxiety, sedation and hypnosis, anti-convulsion and pre-operative sedation. It is not only suitable for the short-term treatment of anxiety disorders and insomnia symptoms in adults, but also can be used for the emergency control of status epilepticus, and is also widely used for sedative administration before endoscopic procedures and surgical operations. It is a basic and commonly used drug in the psychoneurological field.

Driven by the increase in the consultation rate of mental illnesses worldwide and the growing demand for perioperative sedation, the global market size of lorazepam has stabilized at around USD 900 million in recent years, with a compound annual growth rate of 4.2%. In terms of the domestic market, the sales of lorazepam at public medical institution terminals have increased for three consecutive years, exceeding RMB 1.2 billion in 2023. At present, the domestic preparation market is dominated by original research products and leading generic drug companies, and the supply of API has long relied on imports. In recent years, with the acceleration of R&D progress of domestic enterprises, a number of enterprises have submitted API registration applications, and the competitive pattern is gradually evolving towards domestic substitution.

The original research enterprise of lorazepam is Pfizer, and the original brand name is "Ativan". Its core compound patent expired globally in 1999. At present, the dosage forms of the original research product marketed in China are mainly tablets, with three specifications of 0.5mg, 1mg and 2mg. This product has been included in the Catalogue of Marketed Drugs in China, and is the designated reference preparation for domestic generic drug research and development. In terms of API registration, as of now, the CDE API registration platform shows that more than 20 domestic enterprises have submitted lorazepam API registration applications, among which 17 have passed the approval and obtained A status registration numbers. The domestic approved lorazepam preparation varieties have two dosage forms: tablets and injections. (Data as of July 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for lorazepam API. Its products cover all research nodes such as synthetic process intermediates and degradation impurities, and meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. Most of the products are available from stock. For in-stock orders placed before 16:00, delivery can be made on the same day, which can fully meet the reference standard needs of API R&D, quality research and routine production.